Last edition
News about
Domestic Momentum Fails to Offset US Pressure on Pharma Margins: Report
India’s pharmaceutical sector is expected to report steady domestic growth in Q4 FY26, but overall earnings are likely to come under pressure due to continued weakness in the US market, according to a report by Nuvama Institutional Equities.
Amazon Pharmacy to Deliver Foundayo Same-Day, Expanding Access to Eli Lilly's New GLP-1 Pill
Amazon Pharmacy now offers Eli Lilly’s GLP-1 pill Foundayo with real-time availability, transparent pricing from USD 1/day with insurance, USD 5/day cash, and automatic manufacturer-sponsored coupons—soon via in-office kiosks within minutes.
Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting
Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.
Inventia Healthcare Launches Generic Dapagliflozin in US After FDA Approval
Inventia Healthcare has secured FDA approval for dapagliflozin tablets and begun Day-One commercialisation, expanding access to affordable diabetes and heart failure treatment in the US.
OPPI Partners with NIPER-Raebareli to Boost Pharma Research and Scholar Support
The collaboration between OPPI and NIPER-Raebareli will provide research scholarships, industry mentorship and academic support to strengthen innovation and bridge the gap between pharmaceutical research and real-world healthcare needs.
BD Secures CE Mark for Liverty TIPS Stent Graft to Advance Portal Hypertension Treatment in Europe
The next-generation adjustable stent graft expands treatment options for cirrhosis-related complications, with pivotal ARCH trial data set for presentation at SIR 2026.
UK MHRA Secures EUro 3.6 Million to Expand AI Airlock for Safer Medical AI Innovation
Backed by multi-year government funding, the UK’s first AI medical device regulatory sandbox will scale real-world testing, strengthen oversight and accelerate safe adoption of clinical AI technologies.
China Approves GSK's Exdensur for Chronic Rhinosinusitis with Nasal Polyps
GSK plc has received approval from China’s National Medical Products Administration (NMPA) for Exdensur (depemokimab) as an add-on therapy for adult patients with Chronic Rhinosinusitis with Nasal Polyps who remain inadequately controlled with systemic corticosteroids or surgery.
Altruist Biologics Wins First Commercial Manufacturing License for Hangzhou Facility
Altruist Biologics secures its first GMP commercial manufacturing license for its Hangzhou facility, featuring four 20,000L bioreactors. Achieved in just two months, this milestone highlights strong technical expertise and global-quality standards.
GCAR and Purdue Pharma Launch Tinostamustine in GBM AGILE Trial
GCAR and Purdue Pharma LP initiate Tinostamustine enrolment in the GBM AGILE Phase 2/3 trial, advancing potential new treatment options for glioblastoma patients.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy